These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 18055946)

  • 1. Aripiprazole in the treatment of the psychosis prodrome: an open-label pilot study.
    Woods SW; Tully EM; Walsh BC; Hawkins KA; Callahan JL; Cohen SJ; Mathalon DH; Miller TJ; McGlashan TH
    Br J Psychiatry Suppl; 2007 Dec; 51():s96-101. PubMed ID: 18055946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjunctive low-dose aripiprazole with standard-dose sertraline in treating fresh major depressive disorder: a randomized, double-blind, controlled study.
    Lin CH; Lin SH; Jang FL
    J Clin Psychopharmacol; 2011 Oct; 31(5):563-8. PubMed ID: 21869699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses.
    Mintzer JE; Tune LE; Breder CD; Swanink R; Marcus RN; McQuade RD; Forbes A
    Am J Geriatr Psychiatry; 2007 Nov; 15(11):918-31. PubMed ID: 17974864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Open-label aripiprazole in the treatment of acute bipolar depression: a prospective pilot trial.
    McElroy SL; Suppes T; Frye MA; Altshuler LL; Stanford K; Martens B; Leverich GS; Post RM; Keck PE
    J Affect Disord; 2007 Aug; 101(1-3):275-81. PubMed ID: 17229469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, double-blind, placebo-controlled study of aripiprazole for the treatment of psychosis in nursing home patients with Alzheimer disease.
    Streim JE; Porsteinsson AP; Breder CD; Swanink R; Marcus R; McQuade R; Carson WH
    Am J Geriatr Psychiatry; 2008 Jul; 16(7):537-50. PubMed ID: 18591574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The advantage of using 3-week data to predict response to aripiprazole at week 6 in first-episode psychosis.
    Park JI; Cho DH; Hahn SW; Jeong B; Kim JH; Kim SW; Koo MS; Lee SH; Lee SJ; Lee YH; Park JI; Rho SH; Chung YC
    Int Clin Psychopharmacol; 2014 Mar; 29(2):77-85. PubMed ID: 23970176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A 12-week randomized, open-label study of perospirone versus aripiprazole in the treatment of Japanese schizophrenia patients.
    Takekita Y; Kato M; Wakeno M; Sakai S; Suwa A; Nishida K; Okugawa G; Kinoshita T
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Jan; 40():110-4. PubMed ID: 23022672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy, safety, and tolerability of aripiprazole for the treatment of schizoaffective disorder: results from a pooled analysis of a sub-population of subjects from two randomized, double-blind, placebo-controlled, pivotal trials.
    Glick ID; Mankoski R; Eudicone JM; Marcus RN; Tran QV; Assunção-Talbott S
    J Affect Disord; 2009 May; 115(1-2):18-26. PubMed ID: 19230981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aripiprazole monotherapy in the treatment of acute bipolar I mania: a randomized, double-blind, placebo- and lithium-controlled study.
    Keck PE; Orsulak PJ; Cutler AJ; Sanchez R; Torbeyns A; Marcus RN; McQuade RD; Carson WH;
    J Affect Disord; 2009 Jan; 112(1-3):36-49. PubMed ID: 18835043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An open-label pilot study of aripiprazole for male and female veterans with chronic post-traumatic stress disorder who respond suboptimally to antidepressants.
    Youssef NA; Marx CE; Bradford DW; Zinn S; Hertzberg MA; Kilts JD; Naylor JC; Butterfield MI; Strauss JL
    Int Clin Psychopharmacol; 2012 Jul; 27(4):191-6. PubMed ID: 22475888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute treatment of pediatric bipolar I disorder, manic or mixed episode, with aripiprazole: a randomized, double-blind, placebo-controlled study.
    Findling RL; Nyilas M; Forbes RA; McQuade RD; Jin N; Iwamoto T; Ivanova S; Carson WH; Chang K
    J Clin Psychiatry; 2009 Oct; 70(10):1441-51. PubMed ID: 19906348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An open-label assessment of aripiprazole in the treatment of PTSD.
    Robert S; Hamner MB; Durkalski VL; Brown MW; Ulmer HG
    Psychopharmacol Bull; 2009; 42(1):69-80. PubMed ID: 19204652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aripiprazole for drug-naive or antipsychotic-short-exposure subjects with ultra-high risk state and first-episode psychosis: an open-label study.
    Liu CC; Chien YL; Hsieh MH; Hwang TJ; Hwu HG; Liu CM
    J Clin Psychopharmacol; 2013 Feb; 33(1):18-23. PubMed ID: 23277261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and tolerability of switching to aripiprazole from risperidone in subjects with autism spectrum disorders: a prospective open-label study.
    Ishitobi M; Kosaka H; Takahashi T; Yatuga C; Asano M; Tanaka Y; Ueno K; Okazaki R; Omori M; Hiratani M; Tomoda A; Wada Y
    Clin Neuropharmacol; 2013; 36(5):151-6. PubMed ID: 24045605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies.
    Thase ME; Jonas A; Khan A; Bowden CL; Wu X; McQuade RD; Carson WH; Marcus RN; Owen R
    J Clin Psychopharmacol; 2008 Feb; 28(1):13-20. PubMed ID: 18204335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of aripiprazole in subpopulations with acute manic or mixed episodes of bipolar I disorder.
    Suppes T; Eudicone J; McQuade R; Pikalov A; Carlson B
    J Affect Disord; 2008 Apr; 107(1-3):145-54. PubMed ID: 17904226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease.
    Friedman JH; Berman RM; Goetz CG; Factor SA; Ondo WG; Wojcieszek J; Carson WH; Marcus RN
    Mov Disord; 2006 Dec; 21(12):2078-81. PubMed ID: 17013906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and tolerability of aripiprazole for irritability in pediatric patients with autistic disorder: a 52-week, open-label, multicenter study.
    Marcus RN; Owen R; Manos G; Mankoski R; Kamen L; McQuade RD; Carson WH; Findling RL
    J Clin Psychiatry; 2011 Sep; 72(9):1270-6. PubMed ID: 21813076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early intervention with second-generation antipsychotics in first-episode psychosis: results of an 8-week naturalistic study.
    Josiassen RC; Shaughnessy RA; Filymer DM; Donohue AM; Kacso M; Finkel N; Curtis J; Audino B; Skuban N
    Early Interv Psychiatry; 2010 Feb; 4(1):57-63. PubMed ID: 20199481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjunctive aripiprazole in major depressive disorder: analysis of efficacy and safety in patients with anxious and atypical features.
    Trivedi MH; Thase ME; Fava M; Nelson CJ; Yang H; Qi Y; Tran QV; Pikalov A; Carlson BX; Marcus RN; Berman RM
    J Clin Psychiatry; 2008 Dec; 69(12):1928-36. PubMed ID: 19192475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.